Unit
- Nociceptive pain: Arises from activation of nociceptors by tissue injury. In cancer, this often results from tumor infiltration, inflammation, or mechanical compression. Examples include bone metastasis pain or visceral distension. It is typically well-localized and responsive to non-opioid and opioid analgesics.
- Neuropathic pain: Caused by damage to the peripheral or central nervous system from tumor compression, chemotherapy, or radiation. It presents as burning, tingling, or shock-like sensations and often requires adjuvant medications like gabapentinoids or tricyclic antidepressants.
- Mixed pain: Many cancer patients experience both nociceptive and neuropathic components. For instance, a tumor pressing on a nerve may cause somatic pain and neuropathic symptoms, necessitating a multimodal analgesic approach.
- Inflammatory mediators: Tumors release cytokines, prostaglandins, and growth factors that sensitize nociceptors, lowering pain thresholds. This peripheral sensitization contributes to hyperalgesia and allodynia in the tumor microenvironment.
- Central sensitization: Persistent pain signals from peripheral nociceptors can lead to heightened excitability in spinal cord and brain neurons. This amplifies pain perception and may cause pain that persists beyond the initial injury, requiring central-acting therapies.
- Breakthrough pain: Transient exacerbations of otherwise controlled pain, often triggered by movement or end-of-dose failure. It requires rapid-onset rescue medications and careful assessment of baseline analgesic regimen.
- Chronic pain evolution: Acute cancer pain can transition to chronic pain due to ongoing tissue damage, nerve injury, or psychological factors. Early and aggressive treatment may prevent central sensitization and reduce the risk of chronicity.
- Pain pathways: Pain signals travel from peripheral nociceptors via A-delta and C fibers to the dorsal horn, then ascend through spinothalamic tracts to the thalamus and cortex. Descending modulatory pathways from the brain can inhibit or facilitate pain transmission.
- Visceral pain: Arises from hollow organs or viscera due to stretching, ischemia, or inflammation. In cancer, it is common with hepatic, pancreatic, or bowel tumors. It is poorly localized, often referred to distant sites, and may cause autonomic symptoms like nausea or sweating. Management includes opioids and adjuvant agents.
- Somatic pain: Originates from skin, muscle, or bone. In cancer, bone metastases cause deep, aching, well-localized pain. It is generally responsive to NSAIDs, opioids, and localized treatments such as radiation therapy. Somatic pain may worsen with movement or weight bearing.
- Pain assessment tools: Validated instruments like the Numeric Rating Scale, Wong-Baker FACES, or Brief Pain Inventory are used to quantify pain intensity and functional impact. Regular, consistent assessment enables tracking of treatment response and early detection of worsening pain or new pain syndromes.
- Psychosocial factors: Anxiety, depression, fear of death, and social isolation can amplify cancer pain perception. Addressing these through counseling, cognitive behavioral therapy, and support groups is essential for comprehensive pain management and improving quality of life.
Scope of Practice
Role: Pain Management Specialist
Within scope:
- Conduct comprehensive pain assessments including history and physical exam.
- Order and interpret diagnostic tests to identify pain etiology.
- Develop and adjust analgesic regimens using multimodal approaches.
- Coordinate interdisciplinary care with oncology, palliative care, and rehabilitation.
Outside scope:
- Perform surgical interventions for pain without surgical specialty training.
- Provide primary oncologic treatment or disease-modifying therapy.
- Manage non-pain symptoms independently without consultation.
Regulatory Note
Regulation: The Joint Commission Pain Management Standards require comprehensive pain screening and assessment for all patients, with documentation of pain intensity, location, quality, and impact on function.
Standards for Pain Management, The Joint Commission, 2023.
Quick Revision
- Cancer pain involves nociceptive, neuropathic, and mixed mechanisms driven by tumor, treatment, and sensitization processes.
- Understanding pain pathophysiology guides selection of targeted pharmacologic and non-pharmacologic interventions.
- Pain assessment is a regulatory requirement and foundational to effective management.